Bridgewater, NJ, United States of America

Richard Y Huang

This inventor holds 33 USPTO granted patents and 20 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Cancer Therapeutics. Top assignees: Bristol-Myers Squibb Compnay, Five Prime Therapeutics, Inc., Gilead Sciences, Inc.. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Y Huang. Retrieved from https://idiyas.com/inventor/richard-y-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 20)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 13.8

ph-index = 6

Forward Citations = 120(Granted Patents)

Location History:

Plainsboro, NJ (US) (2016 - 2017)
San Mateo, CA (US) (2015 - 2024)
Bridgewater, NJ (US) (2018 - 2024)

Company Filing History:

31 out of 3,742

Bristol-Myers Squibb Compnay

patents

4 out of 77

Five Prime Therapeutics, Inc.

patents

2 out of 946

Gilead Sciences, Inc.

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Cancer Diagnostics

Antibodies

GITR

TIM3

NKG2A

Fibronectin

HLA-E

Therapeutic Compounds

Natural Killer Cells

Peptidylarginine Deiminases

Glucocorticoid

MICA

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492238 - GLYPICAN-3-BINDING FIBRONECTIN BASED SCAFFOLD MOLECULES (2025-12-09),

2. 12435136 - Antibodies binding to ILT4 (2025-10-07),

3. 12312403 - Antibodies against TIM3 and uses thereof (2025-05-27),

4. 12173069 - Antibodies binding to vista at acidic pH (2024-12-24),

5. 12110337 - Anti-CD27 antibodies and uses thereof (2024-10-08),

6. 12091462 - Antibodies binding to vista at acidic pH (2024-09-17),

7. 12077584 - Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A) (2024-09-03),

8. 11981734 - Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A) (2024-05-14),

9. 11878965 - Inhibitors of peptidylarginine deiminases (2024-01-23),

10. 11802162 - Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof (2023-10-31),

11. 11708405 - IP-10 antibodies and their uses (2023-07-25),

12. 11591392 - Antibodies against TIM3 and uses thereof (2023-02-28),

13. 11524992 - Glypican-3-binding fibronectin based scaffold molecules (2022-12-13),

14. 11408889 - Anti-GITR antibodies for cancer diagnostics (2022-08-09),

15. 11401328 - Antibodies binding to ILT4 (2022-08-02),

Title: The Innovative Journey of Richard Y Huang

Introduction: Richard Y Huang, a pioneering inventor based in Bridgewater, NJ (US), has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Richard Y Huang's latest patents include cutting-edge advancements in artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With over two decades of experience in research and development, Richard Y Huang has a proven track record of transforming bold ideas into tangible solutions. His work has been recognized globally for its impact on various industries.

Collaborations: Throughout his career, Richard Y Huang has collaborated with leading universities, research institutions, and multinational companies to push the boundaries of innovation. His ability to work across disciplines has led to the creation of revolutionary technologies.

Conclusion: Richard Y Huang's passion for innovation, coupled with his dedication to solving complex challenges, continues to inspire the next generation of inventors. His relentless pursuit of excellence sets him apart as a visionary in the world of technology.

Profile summary based on public USPTO records.